Predict your next investment

Venture Capital
lvpcapital.com

See what CB Insights has to offer

Investments

92

Portfolio Exits

19

Funds

4

About Latterell Venture Partners

Latterell Venture Partners invests in early stage healthcare companies with innovative technologies, large market opportunities, and passionate entrepreneurs. It offers a blend of venture capital, entrepreneurial, technical, clinical and collaborative skills that enable the firm to help entrepreneurs create highly successful new startups. LVP is committed to building a portfolio of outstanding biotechnology and medical device companies that produce excellent returns for its limited partners while providing major new disease treatments to help patients worldwide.

Latterell Venture Partners Headquarter Location

1 Embarcadero Center Ste 4050

San Francisco, California, 94111,

United States

415-399-9880

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Latterell Venture Partners News

OncoMed Promotes

Jan 10, 2012

By Angela Sormani OncoMed Pharmaceuticals, a clinical-stage company developing therapeutics that target cancer stem cells, has promoted Jakob Dupont, formerly vice president, clinical research to senior vice president and chief medical officer. Privately-held, OncoMed’s investors include US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. PRESS RELEASE OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, today announced the promotion of Jakob Dupont, M.D., formerly Vice President, Clinical Research, to Senior Vice President and Chief Medical Officer. Dr. Dupont joined OncoMed in October from Genentech, a member of the Roche Group, where he had been Global Medical Director for Avastin® (bevacizumab). Dr. Dupont now heads OncoMed’s global development team and is responsible for advancing multiple novel anti-cancer stem cell therapeutics through all phases of clinical development. Prior to joining OncoMed, Dr. Dupont oversaw Genentech’s global medical strategy, and late-stage medical program for Avastin, and served as an Avastin spokesperson to the global investment community. Dr. Dupont received his medical degree at Cornell University Medical College in New York and continued his training in internal medicine at the University of Michigan and New York-Presbyterian Hospital. He completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Dupont has an extensive laboratory research background in immunology, molecular biology, gene therapy and translational medicine. He was a member of the faculty at MSKCC for five years, prior to joining Genentech/Roche, overseeing a Phase 1 Solid Tumor and GYN Oncology Clinic. He was also head of a translational and immunology laboratory at MSKCC. Dr. Dupont has received numerous grants and awards, authored over 40 peer-reviewed scientific articles and holds several patents. He continues to care for gynecologic oncology patients and teach as an Adjunct Clinical Assistant Professor at Stanford University Medical Center. About Cancer Stem Cells Cancer stem cells, a small, resilient subset of cells found in tumors, have the capacity to self-renew and differentiate, leading to tumor initiation and driving tumor growth, recurrence and metastasis. Also referred to as “tumor-initiating cells,” these cells were first discovered by OncoMed’s scientific founders in breast cancer and have subsequently been identified in many other types of solid tumor cancers, including cancer of head and neck, lung, prostate, pancreas and glioblastoma. Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy. OncoMed’s strategy is to improve cancer treatment by specifically targeting the key biologic pathways that are thought to be critical to the activity and survival of cancer stem cells. OncoMed’s antibody therapeutics target cancer stem cell proteins and have the potential to be developed against a range of tumor types. About OncoMed Pharmaceuticals OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed has advanced three anti-cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5 and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed’s pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed has formed strategic alliances with Bayer HealthCare Pharmaceuticals and GlaxoSmithKline. Privately-held, OncoMed’s investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. © 2015 Buyouts Insider / Argosy Group LLC

Latterell Venture Partners Investments

92 Investments

Latterell Venture Partners has made 92 investments. Their latest investment was in Pnkfrg studios as part of their Seed VC on May 5, 2022.

CBI Logo

Latterell Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/16/2022

Seed VC

Pnkfrg studios

$3M

Yes

2

11/29/2020

Series E

Viracta Therapeutics

$40M

No

2

10/28/2019

Series D

Viracta Therapeutics

$16.77M

No

4

4/29/2019

Series G

Subscribe to see more

$99M

Subscribe to see more

10

2/12/2019

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/16/2022

11/29/2020

10/28/2019

4/29/2019

2/12/2019

Round

Seed VC

Series E

Series D

Series G

Series C - II

Company

Pnkfrg studios

Viracta Therapeutics

Viracta Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$3M

$40M

$16.77M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

4

10

10

Latterell Venture Partners Portfolio Exits

19 Portfolio Exits

Latterell Venture Partners has 19 portfolio exits. Their latest portfolio exit was Viracta Therapeutics on November 30, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/30/2020

Reverse Merger

$99M

1

10/1/2020

IPO

$99M

Public

1

6/21/2018

IPO

$99M

Public

6

2/18/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/11/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/30/2020

10/1/2020

6/21/2018

2/18/2016

1/11/2016

Exit

Reverse Merger

IPO

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

6

10

10

Latterell Venture Partners Fund History

4 Fund Histories

Latterell Venture Partners has 4 funds, including Latterell Venture Partners III LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2005

Latterell Venture Partners III LP

Early-Stage Venture Capital

Closed

$200M

1

11/1/2002

Latterell Venture Partners II LP

Subscribe to see more

Subscribe to see more

$99M

10

1/1/2001

Latterell Venture Partners LP

Subscribe to see more

Subscribe to see more

$99M

10

Latterell Venture Partners IV LP

Subscribe to see more

Subscribe to see more

10

Closing Date

12/31/2005

11/1/2002

1/1/2001

Fund

Latterell Venture Partners III LP

Latterell Venture Partners II LP

Latterell Venture Partners LP

Latterell Venture Partners IV LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$200M

$99M

$99M

Sources

1

10

10

10

Latterell Venture Partners Team

9 Team Members

Latterell Venture Partners has 9 team members, including current General Partner, Paul Edwards.

Name

Work History

Title

Status

Peter J. Fitzgerald

Founder

Current

Paul Edwards

General Partner

Current

Patrick F. Latterell

General Partner

Current

Steve Salmon

General Partner

Current

Kenneth J. Widder

General Partner

Current

Name

Peter J. Fitzgerald

Paul Edwards

Patrick F. Latterell

Steve Salmon

Kenneth J. Widder

Work History

Title

Founder

General Partner

General Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.